7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Geoffroy V et al. | High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. | 2002 | Mol. Cell. Biol. | pmid:12167715 |
| Uemura H et al. | Serum osteoprotegerin/osteoclastogenesis-inhibitory factor during pregnancy and lactation and the relationship with calcium-regulating hormones and bone turnover markers. | 2002 | J. Endocrinol. | pmid:12176675 |
| Ragab AA et al. | Cytokines synergistically induce osteoclast differentiation: support by immortalized or normal calvarial cells. | 2002 | Am. J. Physiol., Cell Physiol. | pmid:12176725 |
| Whyte MP et al. | Osteoprotegerin deficiency and juvenile Paget's disease. | 2002 | N. Engl. J. Med. | pmid:12124406 |
| Krane SM | Genetic control of bone remodeling--insights from a rare disease. | 2002 | N. Engl. J. Med. | pmid:12124412 |
| Suzuki Y et al. | [Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment]. | 2002 | Nippon Rinsho | pmid:11979937 |
| Inoue D | [Recent advances in research of bone resorption]. | 2002 | Nippon Rinsho | pmid:11979946 |
| Udagawa N and Takahashi N | [Possible role of receptor activator of NF-kappa B ligand(RANKL) in osteoclast differentiation and function]. | 2002 | Nippon Rinsho | pmid:11979968 |
| Tsuda E | [Osteoclastogenesis inhibitory factor (OCIF)/OPG (a novel therapeutic candidate for the treatment of metabolic bone diseases)]. | 2002 | Nippon Rinsho | pmid:11979969 |
| Koshihara Y | [Recent progress of bone cell culture system (review)]. | 2002 | Nippon Rinsho | pmid:11979973 |
| Kim YH et al. | Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. | 2002 | Exp. Mol. Med. | pmid:12085990 |
| Khosla S et al. | Correlates of osteoprotegerin levels in women and men. | 2002 | Osteoporos Int | pmid:12086350 |
| Ueland T et al. | Effects of 12 months of GH treatment on cortical and trabecular bone content of IGFs and OPG in adults with acquired GH deficiency: a double-blind, randomized, placebo-controlled study. | 2002 | J. Clin. Endocrinol. Metab. | pmid:12050246 |
| Sasaki N et al. | Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. | 2002 | Bone | pmid:12052453 |
| Kudo O et al. | Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. | 2002 | J. Pathol. | pmid:12237882 |
| Hofbauer LC et al. | High bone density due to a mutation in LDL-receptor-related protein 5. | 2002 | N. Engl. J. Med. | pmid:12240686 |
| Okada Y et al. | Cell-to-Cell adhesion via intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 pathway is involved in 1alpha,25(OH)2D3, PTH and IL-1alpha-induced osteoclast differentiation and bone resorption. | 2002 | Endocr. J. | pmid:12402981 |
| Roodman GD | Role of the bone marrow microenvironment in multiple myeloma. | 2002 | J. Bone Miner. Res. | pmid:12412796 |
| Hegedus D et al. | Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. | 2002 | J. Bone Miner. Res. | pmid:12412803 |
| Buckley KA and Fraser WD | Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. | 2002 | Ann. Clin. Biochem. | pmid:12564836 |
| Yang X et al. | Protein Kinase C is a mediator of the synthesis and secretion of osteoprotegerin in osteoblast-like cells. | 2002 | Biochem. Biophys. Res. Commun. | pmid:11779130 |
| David JP et al. | JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. | 2002 | J. Cell. Sci. | pmid:12376563 |
| Jones DH et al. | Role of RANKL and RANK in bone loss and arthritis. | 2002 | Ann. Rheum. Dis. | pmid:12379618 |
| Gravallese EM | Bone destruction in arthritis. | 2002 | Ann. Rheum. Dis. | pmid:12379632 |
| Spyrou P et al. | Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. | 2002 | Clin Oral Implants Res | pmid:12519337 |
| Saidenberg Kermanac'h N et al. | Osteoprotegerin and inflammation. | 2002 Apr-Jun | Eur. Cytokine Netw. | pmid:12101070 |
| Jung K et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. | 2002 Jul-Sep | Int. J. Biol. Markers | pmid:12408468 |
| Younes A and Aggarwall BB | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. | 2003 | Cancer | pmid:12879461 |
| Nawroth P et al. | [Osteoporosis and cardiovascular disease--two sides of the same coin?]. | 2003 | Med. Klin. (Munich) | pmid:12928809 |
| Nakatsuka K et al. | Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. | 2003 | J. Bone Miner. Res. | pmid:12929927 |
| Li JP and Ling JQ | [Tumor necrosis factor and lipopolysaccharide affect periodontal ligament cells expressing osteoprotegerin in vitro]. | 2003 | Zhonghua Kou Qiang Yi Xue Za Zhi | pmid:12930661 |
| Park HR et al. | Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. | 2003 | J. Korean Med. Sci. | pmid:12923331 |
| Naylor KE et al. | Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. | 2003 | J. Clin. Endocrinol. Metab. | pmid:14602774 |
| Paloneva J et al. | DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. | 2003 | J. Exp. Med. | pmid:12925681 |
| Fukushima H et al. | Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. | 2003 | Eur. J. Oral Sci. | pmid:12887401 |
| Ito R et al. | Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. | 2003 | Virchows Arch. | pmid:12838418 |
| Hayashi S et al. | Distinct osteoclast precursors in the bone marrow and extramedullary organs characterized by responsiveness to Toll-like receptor ligands and TNF-alpha. | 2003 | J. Immunol. | pmid:14607912 |
| Terpos E et al. | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. | 2003 | Int. J. Cancer | pmid:12845688 |
| Padigel UM et al. | TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. | 2003 | J. Immunol. | pmid:14607948 |
| Schett G et al. | Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. | 2003 | Arthritis Rheum. | pmid:12847699 |
| Gruber HE and Rude RK | Alterations in osteoclast morphology following osteoprotegerin administration in the magnesium-deficient mouse. | 2003 | Biotech Histochem | pmid:14989640 |
| Wagner TU et al. | The teleost fish medaka (Oryzias latipes) as genetic model to study gravity dependent bone homeostasis in vivo. | 2003 | Adv Space Res | pmid:15000082 |
| Terpos E et al. | New insights into the pathophysiology and management of bone disease in multiple myeloma. | 2003 | Br. J. Haematol. | pmid:14632767 |
| Ha H et al. | Lipid rafts are important for the association of RANK and TRAF6. | 2003 | Exp. Mol. Med. | pmid:14508068 |
| Zhang L et al. | The role of calmodulin in the regulation of osteoclastogenesis. | 2003 | Endocrinology | pmid:12960067 |
| Abrahamsen B et al. | Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. | 2003 | Calcif. Tissue Int. | pmid:12384814 |
| Hortobagyi GN | Novel approaches to the management of bone metastases. | 2003 | Semin. Oncol. | pmid:14613037 |
| Voskaridou E et al. | Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. | 2003 | Br. J. Haematol. | pmid:14616979 |
| Uemura H et al. | Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. | 2003 | Bone | pmid:14623063 |
| Novack DV | TSH, the bone suppressing hormone. | 2003 | Cell | pmid:14567908 |
| Abe E et al. | TSH is a negative regulator of skeletal remodeling. | 2003 | Cell | pmid:14567913 |
| Zhao ZM et al. | [The preliminary study on in vitro differentiation of human umbilical cord blood cells into neural cells]. | 2003 | Zhonghua Xue Ye Xue Za Zhi | pmid:14575594 |
| Boyan BD et al. | Osteoblasts generate an osteogenic microenvironment when grown on surfaces with rough microtopographies. | 2003 | Eur Cell Mater | pmid:14577052 |
| Zhang J et al. | Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. | 2003 | Cancer Res. | pmid:14633717 |
| Chan BY et al. | Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. | 2003 | Clin. Chem. | pmid:14633883 |
| Jung K et al. | Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. | 2003 | J. Urol. | pmid:14634401 |
| Su X et al. | [The effects of 17 beta-estradiol on the expression of osteoprotegerin, the ligand of osteoprotegerin and related cytokines in osteosarcoma MG63 cells]. | 2003 | Zhonghua Nei Ke Za Zhi | pmid:14636471 |
| Kanatani M et al. | Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. | 2003 | J. Cell. Physiol. | pmid:12767054 |
| Ha H et al. | Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. | 2003 | J. Biol. Chem. | pmid:12637570 |
| Ritchlin CT et al. | Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. | 2003 | J. Clin. Invest. | pmid:12639988 |
| Kido S et al. | Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. | 2003 | Bone | pmid:12810169 |
| Kikuchi T et al. | Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. | 2003 | J. Dent. Res. | pmid:12821717 |
| D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
| Knudsen ST et al. | Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. | 2003 | Eur. J. Endocrinol. | pmid:12824864 |
| Fox SW et al. | The possible role of TGF-beta-induced suppressors of cytokine signaling expression in osteoclast/macrophage lineage commitment in vitro. | 2003 | J. Immunol. | pmid:12646633 |
| Varsani H et al. | Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). | 2003 | Rheumatology (Oxford) | pmid:12649407 |
| Wise GE et al. | Regulation of osteoprotegerin gene expression in dental follicle cells. | 2003 | J. Dent. Res. | pmid:12651935 |
| Schoppet M et al. | Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men. | 2003 | Circulation | pmid:12654623 |
| Nimmanapalli R and Bhalla K | Targets in apoptosis signaling: promise of selective anticancer therapy. | 2003 | Methods Mol. Biol. | pmid:12777745 |
| Cheung J et al. | Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. | 2003 | J. Endocrinol. | pmid:12773123 |
| Nakamura H et al. | Suppression of osteoblastic phenotypes and modulation of pro- and anti-apoptotic features in normal human osteoblastic cells under a vector-averaged gravity condition. | 2003 | J. Med. Dent. Sci. | pmid:12968638 |
| Johnson-Pais TL et al. | Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. | 2003 | Int. J. Cancer | pmid:12673693 |
| Zaidi M et al. | Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. | 2003 | J. Bone Miner. Res. | pmid:12674320 |
| Tanaka S et al. | Signal transduction pathways regulating osteoclast differentiation and function. | 2003 | J. Bone Miner. Metab. | pmid:12720046 |
| Valleala H et al. | Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. | 2003 | Eur. J. Endocrinol. | pmid:12720535 |
| Yonou H et al. | Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. | 2003 | Cancer Res. | pmid:12727825 |
| Capparelli C et al. | Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. | 2003 | J. Bone Miner. Res. | pmid:12733724 |
| Wong T et al. | Therapeutic implications for interferon-alpha in arthritis: a pilot study. | 2003 | J. Rheumatol. | pmid:12734885 |
| Al-Qawasmi RA et al. | Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. | 2003 | J. Dent. Res. | pmid:12709501 |
| Fujita D et al. | Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. | 2003 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:12711253 |
| Katavić V et al. | Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. | 2003 | J. Immunol. | pmid:12538719 |
| Clohisy D | Cellular mechanisms of osteolysis. | 2003 | J Bone Joint Surg Am | pmid:12540662 |
| Vanderkerken K et al. | Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. | 2003 | Cancer Res. | pmid:12543775 |
| Liu JZ et al. | [Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15969033 |
| Fahrleitner A et al. | Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. | 2003 | Bone | pmid:12584041 |
| Lanzi R et al. | GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. | 2003 | Eur. J. Endocrinol. | pmid:12590637 |
| Shipman CM and Croucher PI | Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. | 2003 | Cancer Res. | pmid:12615702 |
| Hamzei M et al. | Osteoclast stimulating and differentiating factors in human cholesteatoma. | 2003 | Laryngoscope | pmid:12616193 |
| Siggelkow H et al. | Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. | 2003 | J. Bone Miner. Res. | pmid:12619938 |
| Toraldo G et al. | IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. | 2003 | Proc. Natl. Acad. Sci. U.S.A. | pmid:12490655 |
| Nishimura K et al. | Effects of irradiation on cementum matrix cytokins function during periodontal regeneration. | 2003 | Hum. Cell | pmid:15147042 |
| Choi BK et al. | Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. | 2003 | Infect. Immun. | pmid:12496170 |
| Liu D et al. | Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. | 2003 | Int. J. Mol. Med. | pmid:12469211 |
| Takayanagi H | [Signaling mechanism in the regulation of osteoclast differentiation by the immune system]. | 2003 | Seikagaku | pmid:14748148 |
| Chen X et al. | Effects of genistein on expression of bone markers during MC3T3-E1 osteoblastic cell differentiation. | 2003 | J. Nutr. Biochem. | pmid:12873716 |
| Bridgham JT and Johnson AL | Characterization of chicken TNFR superfamily decoy receptors, DcR3 and osteoprotegerin. | 2003 | Biochem. Biophys. Res. Commun. | pmid:12878204 |
| Riggs BL et al. | Evidence that type I osteoporosis results from enhanced responsiveness of bone to estrogen deficiency. | 2003 | Osteoporos Int | pmid:12879223 |
| Crotti TN et al. | Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. | 2003 | J. Rheumatol. | pmid:14677171 |
| Sasaki T | Differentiation and functions of osteoclasts and odontoclasts in mineralized tissue resorption. | 2003 | Microsc. Res. Tech. | pmid:12879416 |
| Helfrich MH | Osteoclast diseases. | 2003 | Microsc. Res. Tech. | pmid:12879419 |